Cargando…
Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was...
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1979
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009972/ https://www.ncbi.nlm.nih.gov/pubmed/383125 |
| _version_ | 1782136223672827904 |
|---|---|
| author | McElwain, T. J. Hedley, D. W. Burton, G. Clink, H. M. Gordon, M. Y. Jarman, M. Juttner, C. A. Millar, J. L. Milsted, R. A. Prentice, G. Smith, I. E. Spence, D. Woods, M. |
| author_facet | McElwain, T. J. Hedley, D. W. Burton, G. Clink, H. M. Gordon, M. Y. Jarman, M. Juttner, C. A. Millar, J. L. Milsted, R. A. Prentice, G. Smith, I. E. Spence, D. Woods, M. |
| author_sort | McElwain, T. J. |
| collection | PubMed |
| description | In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was a safe time to administer non-cryopreserved marrow. Four patients received lower doses of i.v. melphalan without autologous marrow. In the group receiving autologous marrow the time for recovery of peripheral-blood granulocytes to 800/mm2 or greater was significantly less (P = 0.01) than in those not receiving marrow. In 7 patients the tumour showed evidence of response to the drug and there was 1 complete remission. This treatment deserves investigation in patients with tumours more sensitive to drugs than melanoma. |
| format | Text |
| id | pubmed-2009972 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 1979 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-20099722009-09-10 Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. McElwain, T. J. Hedley, D. W. Burton, G. Clink, H. M. Gordon, M. Y. Jarman, M. Juttner, C. A. Millar, J. L. Milsted, R. A. Prentice, G. Smith, I. E. Spence, D. Woods, M. Br J Cancer Research Article In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was a safe time to administer non-cryopreserved marrow. Four patients received lower doses of i.v. melphalan without autologous marrow. In the group receiving autologous marrow the time for recovery of peripheral-blood granulocytes to 800/mm2 or greater was significantly less (P = 0.01) than in those not receiving marrow. In 7 patients the tumour showed evidence of response to the drug and there was 1 complete remission. This treatment deserves investigation in patients with tumours more sensitive to drugs than melanoma. Nature Publishing Group 1979-07 /pmc/articles/PMC2009972/ /pubmed/383125 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Research Article McElwain, T. J. Hedley, D. W. Burton, G. Clink, H. M. Gordon, M. Y. Jarman, M. Juttner, C. A. Millar, J. L. Milsted, R. A. Prentice, G. Smith, I. E. Spence, D. Woods, M. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title | Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title_full | Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title_fullStr | Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title_full_unstemmed | Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title_short | Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| title_sort | marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. |
| topic | Research Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009972/ https://www.ncbi.nlm.nih.gov/pubmed/383125 |
| work_keys_str_mv | AT mcelwaintj marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT hedleydw marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT burtong marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT clinkhm marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT gordonmy marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT jarmanm marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT juttnerca marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT millarjl marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT milstedra marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT prenticeg marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT smithie marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT spenced marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan AT woodsm marrowautotransplantationaccelerateshaematologicalrecoveryinpatientswithmalignantmelanomatreatedwithhighdosemelphalan |